Pharvaris N.V.
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule designed to alleviate acute HAE attacks, which is also in Phase 2 development. A third candidate, PHVS719, an extended-release prophylactic tablet aimed at preventing HAE episodes, is progressing through Phase 1 trials. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across the Netherlands, Switzerland, and the United States.
Visit website
LLY Eli Lilly and Company |
$1431.67 | -0.82% |
JNJ Johnson & Johnson |
$282.55 | -1.12% |
ABBV AbbVie |
$294.55 | -0.16% |
MRK Merck & Co. |
$144.46 | -2.23% |
UNH UnitedHealth Group Incorp… |
$412.02 | 1.12% |